Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial

Saudi Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 69-76

  Alam, Shahinul ^a   Kabir, Jahangir ^a   Mustafa, Golam ^a   Gupta, Utpaldas ^a   Hasan, Skmnazmul ^a   Alam, Akmkhorshed ^a  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

Author keywords

Bangladesh; fatty liver; fibrosis; histological activity; non alcoholic fatty liver disease; non alcoholic steatohepatitis; Telmisartan

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TELMISARTAN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIOLOGICAL MARKER;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEADACHE; HEPATITIS; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; YOUNG ADULT; DRUG ADMINISTRATION; FIBROSIS; LIFESTYLE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIOMARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84955459538     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.173762     Document Type: Article

References (27)

1. Angulo P. GI epidemiology: Nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-9.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004;40:1387-95.
4. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
5. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: Population based study. Ann Hepatol 2007;6:161-3.
6. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al.; Consensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163-70.
7. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-4.
8. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
9. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-21.
10. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: Human data. Clin Liver Dis 2007;11:75-104, ix.
11. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
12. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma modulating activity. Hypertension 2004;43:993-1002.
13. Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006;12:322-6.
14. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009;15:942-54.
15. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-67.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
18. Alam S, Noor-E-Alam SM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol 2013;5:281-7.
19. Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol 2014;33:452-7.
20. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxyfylline improve Nonalcoholic Steatohepatitis: A randomized placebo-control trial. Hepatology 2011;54:1610-9.
21. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.; NASH CRN. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 2010;362:1675-85.
22. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of Angiotensin II receptor blocker on patient with NASH. Hepatology 2004;40:1222-5.
23. Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003;125:117-25.
24. Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007;52:3455-64.
25. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
26. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of Telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999;53:175-8.
27. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999;17:293-302.